KMT2A and leukemia: First, we in silico (58) down-sampled 10 leukemia samples (marked with two asterisks, Supplementary Table 3 and Supplementary Table 4), containing various aberrations (ETV6::RUNX1, TCF3::PBX1, KMT2A-r, BCR::ABL1, iAMP (21), and five B-other ALL) to 30× coverage and repeated the analysis described above.